Ironwood Pharma (NASDAQ: IRWD) reported Q4 EPS of ($0.10), $0.05 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $130.69 million versus the consensus estimate of $96.57 million.

“The fourth quarter capped off a year of solid LINZESS volume growth and progress with our pipeline of seven differentiated product candidates,” said Peter Hecht, chief executive officer (CEO) of Ironwood. “2018 was a momentous year for Ironwood, as we made the decision to separate into two independent, publicly-traded companies. We are excited to launch these two new companies, each poised to become an industry leader in its respective market, deliver important medicines to patients and unlock value for shareholders.”

Mark Mallon, who is expected to become CEO of Ironwood following completion of the planned separation, added, “It has been an exciting first 40 days here at Ironwood. For the first time ever, Ironwood is making the important transition to a profitable, GI-focused, commercial organization. To do this well, we have set very clear near-term priorities which include accelerating growth of LINZESS and advancing our GI development portfolio. We are taking important strategic actions towards these priorities, including the organizational changes announced this morning, which we believe will help enable Ironwood to launch a more competitive and successful business.”

GUIDANCE:

Ironwood Pharma sees FY2019 revenue of $370-390 million, versus the consensus of $377.33 million.

For earnings history and earnings-related data on Ironwood Pharma (IRWD) click here.